Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

Federico Monaco, MD, Bart L. Scott, MD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Barry E. Storer, PhD, Frederic Baron, Mary E. Flowers, MD, H. Joachim Deeg, MD, Rainer F. Storb, MD, David G. Maloney, MD PhD, Brenda M. Sandmaier, MD

Blood (2017) 130 (Supplement 1): 908.

https://doi.org/10.1182/blood.V130.Suppl_1.908.908

Published: 2017

Journal Articles

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Huiying Qiu, MD, Brenda M. Sandmaier, MD, Barry E. Storer, PhD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Michael A. Pulsipher, Benedetto Bruno, MD, Mary Flowers, MD, Marco Mielcarek, MD, Rainer Storb, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 1949.

https://doi.org/10.1182/blood.V126.23.1949.1949

Published: 2015

Journal Articles

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Theodore A. Gooley, PhD, Thomas Chauncey, MD PhD, John Pagel, MD PhD, Brian G. Till, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, William I. Bensinger, MD, Leona Holmberg, MD PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Stephen D. Smith, MD, Edward N. Libby, MD, David G Maloney, MDPhD, Lorinda A. Soma, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2014) 124 (21): 3967.

https://doi.org/10.1182/blood.V124.21.3967.3967

Published: 2014

Journal Articles

Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant

Colin Phipps, MD, Ajay K. Gopal, MD, Barry E. Storer, PhD, Ryan D. Cassaday, MD, Oliver W. Press, MD, PhD, Brian G. Till, MD, John M. Pagel, MD, PhD, Mary Phillip, Maria Corinna Palanca-Wessels, M.D., Ph.D., William I. Bensinger, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Edward N. Libby, III, MD

Blood (2013) 122 (21): 3365.

https://doi.org/10.1182/blood.V122.21.3365.3365

Published: 2013

Journal Articles

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Rachel B Salit, MD, Filippo Milano, MD, PhD, Jonathan A Gutman, MD, Michael B Maris, MD, Thomas Chauncey, MD, PhD, Finn Petersen, M.D., Colleen Delaney, MD, MSc

Blood (2013) 122 (21): 697.

https://doi.org/10.1182/blood.V122.21.697.697

Published: 2013

Journal Articles

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Merav Bar, MD, Barry Storer, PhD, Benedetto Bruno, MD, Parameswaran Hari, MBBS, MD, MRCP, Thomas Chauncey, MD, PhD, Yoshihiro Inamoto, MD, PhD, Paul J. Martin, MD, Rainer Storb, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Mary E.D. Flowers, MD

Blood (2012) 120 (21): 354.

https://doi.org/10.1182/blood.V120.21.354.354

Published: 2012

Journal Articles

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

William I. Bensinger, MD, Pamela S Becker, MD, PhD, Ted A. Gooley, PhD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Robert Vescio, MD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD, Michael Lill, M.D., Leona Holmberg, MD, PhD, Jainulabdeen J Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 2009.

https://doi.org/10.1182/blood.V120.21.2009.2009

Published: 2012

Journal Articles

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Frederick L Locke, MD, Joseph Pidala, MD, MS, Barry Storer, PhD, Paul J. Martin, MD, Michael A Pulsipher, MD, Thomas Chauncey, MD, PhD, Niels Jacobsen, MD, DMSC, Nikolaus Kroeger, MD, Irwin Walker, MBBS, Mary C Territo, Susan Light, MD, Ginna G Laport, MD, Auayporn Nademanee, MD, Raymond Powles, MD, Armand Keating, MD, Gerard Socie, MD, Claudio Anasetti, MD

Blood (2012) 120 (21): 4195.

https://doi.org/10.1182/blood.V120.21.4195.4195

Published: 2012

Journal Articles

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

Boglarka Gyurkocza, M.D., Rainer Storb, MD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Barry Storer, PhD, Brenda M. Sandmaier, MD

Blood (2012) 120 (21): 4207.

https://doi.org/10.1182/blood.V120.21.4207.4207

Published: 2012

Journal Articles

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

Ryan D. Cassaday, MD, Katherine A. Guthrie, PhD, Lihua E. Budde, MD, PhD, Leslie Thompson, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I. Bensinger, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Damian J. Green, MD, Edward N. Libby, III, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2012) 120 (21): 3082.

https://doi.org/10.1182/blood.V120.21.3082.3082

Published: 2012

Journal Articles

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Laura F Newell, MD, Megan Othus, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Thomas Chauncey, MD, PhD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1446.

https://doi.org/10.1182/blood.V118.21.1446.1446

Published: 2011

Journal Articles

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

Marco Mielcarek, MD, Barry Storer, PhD, Paul J. Martin, MD, Robert S Negrin, MD, Stephen J. Forman, MD, Mary E.D. Flowers, MD, Yoshihiro Inamoto, MD, Thomas Chauncey, MD, PhD, Rainer Storb, MD, Frederick R. Appelbaum, MD, William I Bensinger, MD

Blood (2011) 118 (21): 319.

https://doi.org/10.1182/blood.V118.21.319.319

Published: 2011

Journal Articles

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Leslie A Thompson, Katherine A Guthrie, Lihua Elizabeth Budde, MD, PhD, Brian G. Till, MD, Oliver W. Press, MD, PhD, Thomas Chauncey, MD, PhD, John M. Pagel, MD, PhD, Stephen H. Petersdorf, MD, William I Bensinger, MD, Leona Holmberg, MD., PhD, Andrei R. Shustov, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 2026.

https://doi.org/10.1182/blood.V118.21.2026.2026

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Marcello Rotta, MD, Barry E Storer, Thoralf Lange, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Peter A. McSweeney, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick R Appelbaum, MD, William Bensinger, MD, Brenda M Sandmaier, MD, Rainer F Storb, George E. Georges, MD, David G Maloney, MD, PhD

Blood (2009) 114 (22): 3391.

https://doi.org/10.1182/blood.V114.22.3391.3391

Published: 2009

Journal Articles

Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia.

Ron Ram, MD, Rainer F. Storb, MD, David G. Maloney, MD, Brenda M. Sandmaier, MD, Michael Maris, MD, Judith Shizuru, MD, PhD, Thomas Chauncey, MD, PhD, Amelia A. Langston, MD, George E. Georges, MD

Blood (2009) 114 (22): 1210.

https://doi.org/10.1182/blood.V114.22.1210.1210

Published: 2009

Journal Articles

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael Pulsipher, MD, Parameswaran Hari, MD, MS, Richard Thomas Maziarz, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick Appelbaum, MD, William Bensinger, MD, Brenda Sandmaier, MD, PhD, Rainer Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 1130.

https://doi.org/10.1182/blood.V112.11.1130.1130

Published: 2008

Journal Articles

Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).

Monica Thakar, MD, Barry Storer, PhD, Thomas Chauncey, MD, PhD, Michael Pulsipher, MD, David Maloney, MD, PhD, Rainer Storb, MD, Brenda Sandmaier, MD

Blood (2007) 110 (11): 480.

https://doi.org/10.1182/blood.V110.11.480.480

Published: 2007

Journal Articles

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Andrew R. Rezvani, MD, Brenda M. Sandmaier, MD, Barry Storer, PhD, Michael Maris, MD, Edward Agura, MD, Richard Maziarz, MD, James C. Wade, MD, Thomas Chauncey, MD, PhD, Stephen J. Forman, MD, Dietger W. Niederwieser, MD, Judith Shizuru, MD, Amelia Langston, MD, Michael Pulsipher, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2006) 108 (11): 3124.

https://doi.org/10.1182/blood.V108.11.3124.3124

Published: 2006

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

Michael B. Maris, MD, Brenda M. Sandmaier, MD, Barry Storer, PhD, Edward Agura, MD, James Wade, MD, Richard T. Maziarz, MD, Stephen Forman, MD, Judy Shizuru, MD, PhD, Thomas Chauncey, MD, PhD, Christoph Kahl, MD, Amelia A. Langston, MD, Dietger Niederwieser, MD, Rainer Storb, MD, David G. Maloney, MD

Blood (2005) 106 (11): 1130.

https://doi.org/10.1182/blood.V106.11.1130.1130

Published: 2005

Journal Articles

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Marco Mielcarek, MD, Lauri Burroughs, MD, Wendy Leisenring, PhD, Paul Martin, MD, Razvan Diaconezcu, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, PhD, Michael Maris, MD, Judith Shizuru, MD, Karl Blume, MD, Ute Hegenbart, MD, Dietger Niederwieser, MD, Stephen Forman, MD, Benedetto Bruno, MD, Ann Woolfrey, MD, Rainer Storb, MD

Blood (2004) 104 (11): 423.

https://doi.org/10.1182/blood.V104.11.423.423

Published: 2004

NARROW

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia.

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only